NL
DE
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.
Rob Aarnoutse will focus his professorship on optimization of drug treatment of tuberculosis (TB), which is the leading cause of death due to an infectious disease worldwide. Each year 1.5 million people die from this disease. His research line extends from preclinical (molecular) pharmacological research to clinical pharmacological work, pharmacokinetic substudies in larger clinical trials, and research on dose optimization in clinical practice (‘molecule to man’). In order to establish this translational and application-oriented research line, he developed a sustainable network with partners in Radboudumc, elsewhere in The Netherlands and Europe, and in lndonesia, Tanzania and South Africa. He coached 12 PhD students as co-supervisor (co-promotor) and is (co)author of 170 international scientific publications.
Rob Aarnoutse studied Pharmacy in Utrecht and was trained as hospital pharmacist at the Albert Schweitzer hospital in Dordrecht, The Netherlands. Since 1999 he has been working at Radboudumc. In 2003 he obtained a PhD title based on his thesis ‘Application of pharmacokinetics to improve antiretroviral treatment’. Besides his research activities, he is actively involved in patient care as hospital pharmacist, dedicated as trainer for hospital pharmacy trainees, and trainer for clinical pharmacology at Radboudumc. Internationally he is member of the chief investigators group of the PanACEA TB research consortium, initiated the leading annual meeting in the TB pharmacology field, and started several international proficiency testing programmes for measurement of drugs in blood.
R.E. Aarnoutse, PharmD PhD, appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’. Appointment on 16 November 2020, for a period of 5 years.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger
2 November 2021 On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC. read more
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)
12 May 2020 In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens. read more
The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV
17 March 2020 In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations. read more
Importance of prospective studies in pregnant and breastfeeding women living with HIV
14 March 2019 In Clinical Infectious Diseases Angela Colbers, Stein Schalkwijk and David Burger give considerations on how to effectively evaluate aspects of clinical pharmacology required for safe and effective treatment to optimize pharmacotherapy during pregnancy and breastfeeding. read more
Beyond the scientist: Roger Brüggemann
13 November 2018 Roger, who subscribed for the national pilot academy in 1992, eventually became a hospital pharmacist and associate professor of clinical pharmacology. This summer he became a “Cinglé du Ventoux”. read more
